Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2006-11-21
2006-11-21
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S009300, C424S009100, C424S001110, C424S001690, C530S330000, C530S331000, C534S010000, C534S014000
Reexamination Certificate
active
07138104
ABSTRACT:
The present invention describes a method of concurrent imaging in a mammal comprising:a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; andb) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; andc) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.
REFERENCES:
patent: 4248802 (1981-02-01), Kuntz
patent: 4765971 (1988-08-01), Wester et al.
patent: 4859777 (1989-08-01), Toner
patent: 4988827 (1991-01-01), Bergstein et al.
patent: 5028699 (1991-07-01), Iqbal et al.
patent: 5064956 (1991-11-01), Kruper
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5281704 (1994-01-01), Love et al.
patent: 5350837 (1994-09-01), Bridger et al.
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5412148 (1995-05-01), Keana
patent: 5417959 (1995-05-01), Wallace
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5527521 (1996-06-01), Unger
patent: 5547656 (1996-08-01), Unger et al.
patent: 5556939 (1996-09-01), Flanagan et al.
patent: 5567411 (1996-10-01), Keana et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5679810 (1997-10-01), Love et al.
patent: 5744120 (1998-04-01), Edwards et al.
patent: 5750088 (1998-05-01), Sworin et al.
patent: 5760191 (1998-06-01), Snow et al.
patent: 5769080 (1998-06-01), Unger et al.
patent: 5773024 (1998-06-01), Unger et al.
patent: 5801228 (1998-09-01), Hollister et al.
patent: 5804161 (1998-09-01), Long et al.
patent: 5879659 (1999-03-01), Edwards et al.
patent: 6026317 (2000-02-01), Verani
patent: 6051207 (2000-04-01), Klaveness et al.
patent: 6146657 (2000-11-01), Unger et al.
patent: 6254852 (2001-07-01), Glajch et al.
patent: 6322770 (2001-11-01), Rajopadhye et al.
patent: 6524553 (2003-02-01), Harris
patent: 6838074 (2005-01-01), Carpenter, Jr.
patent: 0107734 (1987-07-01), None
patent: 0727225 (1996-08-01), None
patent: WO9114460 (1991-10-01), None
patent: WO9217215 (1992-10-01), None
patent: WO9640637 (1996-12-01), None
patent: WO9733627 (1997-09-01), None
patent: WO9823608 (1998-06-01), None
Antunes, M.L. et al., “Diagnosis of Right Ventricular Acute Myocardial Infarction by Dual Isotope Thallium-201 and Indium-111 Antimyosin SPECT Imaging”, Am. J. Cardiol., 70, pp. 426-431 (1992).
Ashton, P.R. et al., “Amino Acid Derivatives of β-Cyclodextrin”, J. Org. Chem., 61, pp. 903-908 (1996).
Bakker, W.H. et al., [111In-DTPA-D-Phe1]-octreotide, a Potential Radiopharmaceutical for Imaging of Somatostatin Receptor-Positive Tumors: Synthesis, Radiolabeling and In Vitro Validation, Life Sciences, vol. 49, pp. 1583-1591 (1991).
Bousquet, J. et al., “Gd-DOTA: Characterization of a New Paramagnetic Complex”, Radiology, 166, pp. 693-698 (1988).
Brechbiel, M.W. et al., “Backbone-Substituted DTPA Ligands for90Y Radioimmunotherapy”, Bioconjugate Chem., 2, pp. 187-194 (1991).
Brechbiel, M.W. et al., “Synthesis of C-Functionalizedtrans-Cyclohexyldiethylenetriaminepenta-acetic Acids for Labelling of Monoclonal Antibodies with the Bismuth-212 α-Particle Emitter”, J. Chem. Soc. Perkin Trans., 1, 1173-1178 (1992).
Brinkley, M., “A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Cross-Linking Reagents”, Bioconjugate Chem., 3, pp. 2-13 (1992).
Coker, M.L. et al., “Myocardial matrix metalloproteinase activity and abundance with congestive heart failure”, Am. J. Physiol., vol. 274, pp. H1516-H1523 (1998).
Deshpande, S.V. et al., “Yttrium-90-Labeled Monoclonal Antibody for Therapy: Labeling by a New Macrocyclic Bifunctional Chelating Agent”, J. Nucl. Med., 31, pp. 473-479 (1990).
Folkman, J., “Angiogenesis in cancer, vascular, rheumatoid and other disease”, Nature Medicine, vol. 1, No. 1, pp. 27-31 (1995).
Friedlander, M. et al., “Definition of Two Angiogenic Pathways by Distinct αv Integrins”, Science, vol. 270, pp. 1500-1502 (1995).
Hillel, P.G. et al., “The use of dual-isotope imaging to compare the gastrointestinal transit of food and pancreatic enzyme pellets in cystic fibrosis patients”, Nuclear Medicine Communications, 19, pp. 761-769 (1998).
Hubbuch, A. et al., “Synthese N-geschützter Cysteins äurederivative und ihrer aktivierten Ester”, Liebigs Ann. Chem., pp. 776-783 (1979).
Krenning, E.P. et al., “Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients”, European Journal of Nuclear Medicine, vol. 20, No. 8, pp. 716-731 (1993).
Krenning, E.P. et al., “Somatostatin Receptor: Scintigraphy and Radionuclide Therapy”, Digestion, 57 (suppl 1), pp. 57-61 (1996).
Magerstädt, M. et al., “Gd(DOTA): An Alternative to Gd(DTPA) as a T1.2Relaxation Agent for NMR Imaging or Spectroscopy”, Magn. Reson. Med., 3, pp. 808-812 (1986).
Manning, D.D. et al., “Neoglycopolymer Inhibitors of the Selectins”, Tetrahedron, vol. 53, No. 35, pp. 11937-11952 (1997).
McNulty, P.H. et al., “Glycogen depletion contributes to ischemic preconditioning in the rat heart in vivo”, Am. J. Physiol., vol. 271 (6, Pt. 2), pp. H2283-H2289 (1996).
Mousa, S.A. et al., “Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications”, DDT, vol. 2, No. 5, pp. 187-199 (1997).
Runge, V.M. et al., “MR Imaging of Rat Brain Glioma: Gd-DTPA versus Gd-DOTA”, Radiology, 166, pp. 835-838 (1988).
Samanen, J. et al., “Vascular Indications for Integrin αv Antagonists”, Current Pharmaceutical Design, 3, pp. 545-584 (1997).
Sellke et al., “Angiogenesis in Cardiovascular Disease”, Drugs, 58 (3), pp. 391-396 (1999).
Senger, D.R. et al., “Angiogenesis promoted by vascular endothelial growth factor: Regulation through α1β1 and α2β1 integrins”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 13612-13617 (1997).
Srivatsa, S.. et al., “Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury . . . ”, Cardiovascular Research, 36, pp. 408-428 (1997).
White, S.A. et al., “Case Report: Spectral Overlap Artifact During Dual Isotope Imaging with Tc-99m and In-111”, Journal of Nuclear Medicine Technology, vol. 12, No. 3, pp. 124-125 (1984).
Wilbur, D.S. et al., “Streptavidin in Antibody Pretargeting. 2. Evaluation of Methods for Decreasing Localization of Streptavidin to Kidney while Retaining Its Tumor Binding Capacity”, Bioconjugate Chem., 9, pp. 322-330 (1998).
Youker, K.A. et al., “Time-Dependent Neutrophil β1 and β3 Integrin Expression in the Reperfused Myocardium: Role in Tissue Migration”, Circulation, Supplement I, vol. 100, No. 18 (1433), p. I-275 (1999).
U.S. Appl. No. 09/995,388, filed, Nov. 27, 2001, Carpenter.
U.S. Appl. No. 10/214,429, filed, Aug. 7, 2002, Carpenter.
Bristol--Myers Squibb Company
Golian Paul D.
Lamerdin John A.
Padmanabhan Sreeni
Sharareh Shahnam
LandOfFree
Simultaneous imaging of cardiac perfusion and a vitronectin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Simultaneous imaging of cardiac perfusion and a vitronectin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Simultaneous imaging of cardiac perfusion and a vitronectin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631274